Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01494
|
|||||
| Drug Name |
Roscovitine
|
|||||
| Synonyms |
Seliciclib; roscovitine; 186692-46-6; R-Roscovitine; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; Roscovitine; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Cystic fibrosis [ICD11: CA25] | Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H26N6O
|
|||||
| Canonical SMILES |
CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3
|
|||||
| InChI |
InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
|
|||||
| InChIKey |
BTIHMVBBUGXLCJ-OAHLLOKOSA-N
|
|||||
| CAS Number |
CAS 186692-46-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 354.4 | Topological Polar Surface Area | 87.9 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
527377
, 584365
, 610560
, 6436229
, 7890318
, 10253958
, 11108321
, 11120183
, 11120671
, 11121159
, 11121724
, 11122204
, 11147266
, 11362832
, 11365394
, 11367956
, 11370895
, 11370896
, 11373557
, 11376118
, 11440772
, 12015583
, 14719432
, 14720319
, 14778719
, 14876445
, 24278682
, 26753649
, 26753650
, 26759456
, 26759458
, 46235405
, 46393775
, 47364935
, 47364936
, 47439996
, 47736219
, 47736220
, 48034852
, 48034853
, 48184761
, 50066372
, 50087155
, 50100113
, 50107006
, 50107007
, 53789190
, 57349053
, 68533699
, 80722361
|
|||||
| ChEBI ID |
CHEBI:45307
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT02649751) Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | |||||
| 2 | ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos. 2010 Nov;38(11):2000-6. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.